NIH Study Shows Schizophrenia and Other Psychological Conditions Healed By Cannabis NOT Caused By....
In fact, This NIH (National Institutes of Health Study demonstrates that Cannabis components THC and CBD would be a more effective and safer medication than Antidepressants and Antipsychotic medicines.
The reason why: these dysfunctions are now being shown to be rooted in abnormalities in the body’s extensive Cannabinoid Receptor System (EC system). The EC system dysfunctions result in brain chemistry imbalances. Antidepressants and Antipsychotic medicines treat brain chemistry changes consequent of cannabinoid deficiencies whereas Cannabis treats the root cause by going directly to the EC system.
Acta Psychiatr Scand. 2011 Oct;124(4):250-61. doi: 10.1111/j.1600-0447.2011.01687.x. Epub 2011 Mar 9.
Endocannabinoid system dysfunction in mood and related disorders.
Ashton CH, Moore PB.
Department of Psychiatry, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.
Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Objective: The endocannabinoid (EC) system is widely distributed throughout the brain and modulates many functions. It is involved in mood and related disorders, and its activity may be modified by exogenous cannabinoids. This article examines the therapeutic potential of cannabinoids in psychiatric disorders. Method: An overview is presented of the literature focussed on the functions of the EC system, its dysfunction in mood disorders and the therapeutic potential of exogenous cannabinoids. Results: We propose (hypothesize) that the EC system, which is homoeostatic in cortical excitation and inhibition, is dysfunctional in mood and related disorders. Anandamide, tetrahydrocannabinol (THC) and cannabidiol (CBD) variously combine antidepressant, antipsychotic, anxiolytic, analgesic, anticonvulsant actions, suggesting a therapeutic potential in mood and related disorders. Currently, cannabinoids find a role in pain control. Post mortem and other studies report EC system abnormalities in depression, schizophrenia and suicide. Abnormalities in the cannabinoid-1 receptor (CNR1) gene that codes for cannabinoid-1(CB1) receptors are reported in psychiatric disorders. However, efficacy trials of cannabinoids in psychiatric disorders are limited but offer some encouragement. Conclusion: Research is needed to elucidate the role of the EC system in psychiatric disorders and for clinical trials with THC, CBD and synthetic cannabinoids to assess their therapeutic potential.
© 2011 John Wiley & Sons A/S.
[PubMed - in process]
LinkOut - more resources
Full Text Sources
• Blackwell Publishing
• OhioLINK Electronic Journal Center
• Swets Information Services
Edited by froggymountain, 16 October 2011 - 12:55 PM.